CytosinLab Therapeutics Overview
- Year Founded
-
2019

- Status
-
Private
- Latest Deal Type
-
Series A1
- Latest Deal Amount
-
$13.7M
- Investors
-
10
CytosinLab Therapeutics General Information
Description
Developer of innovative drugs and therapies intended to treat cancer. The company develops new drugs and therapies based on epigenetics research, committing to promoting next-generation cancer treatment revolution, enabling cancel solution for patients.
Contact Information
Website
www.cytosinlab.comCorporate Office
- Room 2801B21, Building A, Phase I, Sunshine Science and Technology Innovation Center, Nanx
- Nanshan Community, Nanshan District
- Shenzhen, Guangdong 518000
- China
Corporate Office
- Room 2801B21, Building A, Phase I, Sunshine Science and Technology Innovation Center, Nanx
- Nanshan Community, Nanshan District
- Shenzhen, Guangdong 518000
- China
CytosinLab Therapeutics Timeline
CytosinLab Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC (Series A1) | 26-Sep-2023 | $13.7M | Completed | Clinical Trials - General | ||
3. Early Stage VC (Series A) | 18-Nov-2021 | Completed | Clinical Trials - General | |||
2. Early Stage VC | 02-Mar-2021 | Completed | Clinical Trials - General | |||
1. Early Stage VC | 26-Apr-2020 | Completed | Startup |
CytosinLab Therapeutics Patents
CytosinLab Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240376126-A1 | Prmt5 inhibitor and the use thereof | Pending | 01-Jul-2022 | ||
AU-2023296592-A1 | Class of prmt5 inhibitors and use thereof | Pending | 01-Jul-2022 | ||
AU-2023209975-A1 | Salt crystal form and free base crystal form of kinase inhibitor | Inactive | 21-Jan-2022 | ||
EP-4467541-A1 | Salt crystal form and free base crystal form of kinase inhibitor | Inactive | 21-Jan-2022 | ||
EP-4342878-A1 | Arginine methyltransferase inhibitor and use thereof | Pending | 21-May-2021 | A61K31/55 |
CytosinLab Therapeutics Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Fortune Capital | Venture Capital | Minority | ||
Heda Ventures | Venture Capital | Minority | ||
CDH Investments | PE/Buyout | Minority | ||
Dawu Venture Capital | Venture Capital | Minority | ||
Kaitai Capital | Venture Capital | Minority |
CytosinLab Therapeutics FAQs
-
When was CytosinLab Therapeutics founded?
CytosinLab Therapeutics was founded in 2019.
-
Where is CytosinLab Therapeutics headquartered?
CytosinLab Therapeutics is headquartered in Shenzhen, China.
-
What industry is CytosinLab Therapeutics in?
CytosinLab Therapeutics’s primary industry is Drug Discovery.
-
Is CytosinLab Therapeutics a private or public company?
CytosinLab Therapeutics is a Private company.
-
What is CytosinLab Therapeutics’s current revenue?
The current revenue for CytosinLab Therapeutics is
. -
How much funding has CytosinLab Therapeutics raised over time?
CytosinLab Therapeutics has raised $45M.
-
Who are CytosinLab Therapeutics’s investors?
Fortune Capital, Heda Ventures, CDH Investments, Dawu Venture Capital, and Kaitai Capital are 5 of 10 investors who have invested in CytosinLab Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »